<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-21</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-21</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>98</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Natureé¦–æ¬¡æ­ç¤ºæŸ“è‰²è´¨è°ƒèŠ‚å› å­SATB1è°ƒæ§Tç»†èƒï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—å¼€è¾Ÿæ–°é€”å¾„ï¼›CellæŠ€æœ¯çªç ´STAMPå®ç°ç™¾ä¸‡å•ç»†èƒåˆ†æã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒç ”ç©¶</strong>ï¼šå•ç»†èƒåˆ†æè¯†åˆ«HLA-DR+è‚¿ç˜¤ç»†èƒã€PLAUR+ä¸­æ€§ç²’ç»†èƒã€MMP11+æˆçº¤ç»´ç»†èƒï¼ŒåŠå…¶å¯¹Tç»†èƒå’Œå…ç–«æ²»ç–—æ•ˆæœçš„å½±å“ï¼›ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œå¾®ç¯å¢ƒç‰¹å¾ã€‚<br />
- <strong>å…ç–«æ²»ç–—æ–°æœºåˆ¶æ¢ç´¢</strong>ï¼šCD47â€œåˆ«åƒæˆ‘â€ä¿¡å·åˆ†å­ä¿ƒè¿›Tç»†èƒè€—ç«­ï¼›CAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼PARPiè€è¯ã€‚<br />
- <strong>ç¥ç»å…ç–«ä¸ç–¾ç—…æœºåˆ¶</strong>ï¼šèƒ¶è´¨ç˜¤ç¥ç»å…ç–«é€ƒé€¸æ–°æœºåˆ¶ï¼›ç™«ç—«å‘ç—…å‰è¡€æµ†è›‹ç™½è´¨å˜åŒ–è§„å¾‹ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>ç©ºé—´ç»„å­¦æŠ€æœ¯</strong>ï¼šVisium HDã€Stereo-seq V2ï¼ˆFFPEåˆ‡ç‰‡å•ç»†èƒç²¾åº¦å…¨è½¬å½•ç»„å®šä½ï¼‰ç­‰å¹³å°æ€§èƒ½æµ‹è¯„ã€‚<br />
- <strong>å•ç»†èƒæ•°æ®å¤„ç†</strong>ï¼šPythonå¤„ç†ç–‘éš¾æ‚ç—‡æ•°æ®ã€RåŒ…å¤„ç†GEOæ•°æ®ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
è‚¿ç˜¤å…ç–«ç–—æ³•æ–°ç­–ç•¥ï¼šåˆ©ç”¨é¶å‘è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçš„å…ç–«ç»†èƒå› å­ï¼ŒååŒTç»†èƒå’ŒNKç»†èƒå¢å¼ºæŠ—ç™Œæ•ˆæœã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«ï¼šç ”ç©¶è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒã€NKç»†èƒã€Tç»†èƒåœ¨ç™Œç—‡å…ç–«ä¸­çš„ä½œç”¨åŠè°ƒæ§æœºåˆ¶ã€‚<br />
- ç»†èƒä»£è°¢ä¸è¯ç‰©æŠµæŠ—ï¼šæ¢ç´¢DDX6ç›¸åˆ†ç¦»è°ƒæ§AMLä»£è°¢å¯å¡‘æ€§å’Œè€è¯æ€§ã€‚<br />
- ç¥ç»é€€è¡Œæ€§ç–¾ç—…å…ç–«ï¼šç ”ç©¶Tç»†èƒåœ¨äº¨å»·é¡¿ç—…ç¥ç»é€€è¡Œä¸­çš„ç‰©ç§ç‰¹å¼‚æ€§å…ç–«æµ¸æ¶¦ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- CITE-seqå’Œå•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰æŠ€æœ¯åœ¨è‚¿ç˜¤å…ç–«å’Œç–¾ç—…ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚<br />
- CRISPRç­›é€‰æŠ€æœ¯ç”¨äºè§£æAMLè¯ç‰©æŠµæŠ—æœºåˆ¶ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å…ç–«ç»†èƒå› å­ä¸é¶å‘æŠ—ä½“è”åˆæ²»ç–—æ™šæœŸå®ä½“è‚¿ç˜¤å±•ç°æ½œåŠ›ï¼›FaceAgeä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©åœ¨å¤§å‹è‚¿ç˜¤é˜Ÿåˆ—ä¸­ç”¨äºé¢„åå’Œæ²»ç–—åˆ†å±‚ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯„ä¼°Cergutuzumab amunaleukinè”åˆé˜¿æ›¿ä½åˆ©ç å•æŠ—æ²»ç–—æ™šæœŸCEAé˜³æ€§å®ä½“è‚¿ç˜¤çš„å®‰å…¨æ€§ä¸æ´»æ€§ã€‚<br />
- æ¢ç´¢åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ç›¸å…³èƒ†é“ç™Œçš„ä¸´åºŠåŸºå› ç»„å­¦ç‰¹å¾åŠæ²»ç–—ç­–ç•¥ã€‚<br />
- åˆ†æèƒ°è…ºç™Œä¸­é›Œæ¿€ç´ ç”Ÿæˆå¯¹è‚¿ç˜¤å¾®ç¯å¢ƒçš„å½±å“æœºåˆ¶ã€‚<br />
- è¯„ä¼°FaceAgeï¼ˆåŸºäºé¢éƒ¨ç…§ç‰‡çš„ç”Ÿç‰©å¹´é¾„ä¼°ç®—ç³»ç»Ÿï¼‰ä½œä¸ºè‚¿ç˜¤é¢„åå’Œæ²»ç–—åˆ†å±‚çš„ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- è”åˆä½¿ç”¨å…ç–«ç»†èƒå› å­ï¼ˆIL-2å˜å¼‚ä½“ï¼‰ä¸é¶å‘æŠ—ä½“ï¼ˆCergutuzumab amunaleukinï¼‰ã€‚<br />
- åˆ©ç”¨æ·±åº¦å­¦ä¹ ç³»ç»ŸFaceAgeä¼°ç®—ç”Ÿç‰©å¹´é¾„ï¼Œé¢„æµ‹ç”Ÿå­˜ç‡å’Œæ—©æœŸæ­»äº¡ç‡ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹åˆ†å­åœ¨é˜¿å°”èŒ¨æµ·é»˜ç—…æ¨¡å‹ä¸­æ˜¾è‘—é€†è½¬ç—…ç—‡ï¼›ç§‘å­¦å®¶æˆåŠŸé‡å¡‘å…ç–«ç»†èƒï¼Œæ˜¾è‘—å¢å¼ºæŠ—ç™Œèƒ½åŠ›ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡å…ç–«ç–—æ³•ï¼šé€šè¿‡é‡å¡‘Tç»†èƒåŠŸèƒ½ï¼Œå…‹æœè‚¿ç˜¤å…ç–«æŠ‘åˆ¶ï¼Œæå‡æ²»ç–—æ•ˆæœã€‚<br />
- ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼šå¼€å‘é¶å‘Î²-æ·€ç±³æ ·è›‹ç™½æ–‘å—çš„æ–°å‹å°åˆ†å­ï¼Œåœ¨åŠ¨ç‰©æ¨¡å‹ä¸­å±•ç°è®°å¿†æ¢å¤å’Œç‚ç—‡ç¼“è§£ã€‚<br />
- ç»„ç»‡å†ç”Ÿï¼šæ­ç¤ºè‚Œè‚‰å¹²ç»†èƒå¦‚ä½•é€šè¿‡RNAè°ƒæ§å¼•å¯¼å·¨å™¬ç»†èƒï¼Œé©±åŠ¨è¾èˆå°¾éƒ¨å†ç”Ÿã€‚<br />
- ç½•è§ç—…è¯Šæ–­ï¼šåˆ©ç”¨RNAæµ‹åºæŠ€æœ¯ï¼Œè¯†åˆ«DNAæ£€æµ‹é—æ¼çš„åŸºå› è¡¨è¾¾å¼‚å¸¸ï¼Œæé«˜ç½•è§ç—…è¯Šæ–­å‡†ç¡®æ€§ã€‚<br />
- éª¨é«“å¾®ç¯å¢ƒä¸ç–¾ç—…ï¼šé˜æ˜æ…¢æ€§ç‚ç—‡å¦‚ä½•é‡å¡‘éª¨é«“ï¼Œä¿ƒè¿›çªå˜å¹²ç»†èƒå…‹éš†å¢æ®–ï¼Œä¸ç–¾ç—…å‘ç”Ÿç›¸å…³ã€‚<br />
- è‚¾è„ç–¾ç—…æ²»ç–—ï¼šç ”å‘æ–°å‹æŠ—ä½“ï¼Œé¶å‘å¤šå›Šè‚¾è„ç–¾ç—…çš„å…³é”®ä¿¡å·é€šè·¯ï¼Œåœ¨åŠ¨ç‰©ç ”ç©¶ä¸­æ˜¾ç¤ºå‡ºå‡ç¼“æˆ–é€†è½¬ç—…æƒ…çš„æ½œåŠ›ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>RNAæµ‹åº</strong>ï¼šå®ç°å¯¹FFPEæ ·æœ¬çš„å…¨è½¬å½•ç»„å•ç»†èƒåˆ†æï¼Œæ‹“å±•äº†åŸºå› è¡¨è¾¾ç ”ç©¶çš„æ ·æœ¬ç±»å‹å’Œåˆ†è¾¨ç‡ã€‚<br />
- <strong>æ–°å‹æŠ—ä½“å·¥ç¨‹</strong>ï¼šè®¾è®¡èƒ½å¤Ÿæ¸—é€è‚¾è„å›Šè‚¿å¹¶é˜»æ–­ç‰¹å®šç”Ÿé•¿ä¿¡å·çš„æŠ—ä½“ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (38æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œé€šè¿‡å•ç»†èƒåˆ†æè¯†åˆ«HLA-DR +è‚¿ç˜¤ç»†èƒï¼Œå¹¶åˆ†æå…¶å¯¹ CD8+T ç»†èƒåŠé¢„åçš„å½±å“ï¼Œæ€è·¯æ–°é¢–ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€Tç»†èƒã€å•ç»†èƒã€ç”Ÿä¿¡ã€é€šè·¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=7&amp;sn=c83766b30c9d2ebf79d51526dd63b27e" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>æœ€æ–°10+ç”Ÿä¿¡ï¼Œéå¸¸åŠ¡å®çš„æ–‡ç« ã€‚è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä¸­å…³é”®å…ç–«ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ³›ç™Œç©ºé—´ç‰¹å¾åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å¾®ç”Ÿç‰©ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=1&amp;sn=dc81d8f1a2a2a43ece30c6a89d7de64c" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œå•ç»†èƒè¯†åˆ«PLAUR+ä¸­æ€§ç²’ç»†èƒå¡‘é€ å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒï¼ŒæŠ‘åˆ¶PLAUR å¢å¼ºæŠ— PD1 ç–—æ•ˆã€‚é«˜åˆ†æ–‡ç« ç»å…¸æ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=5&amp;sn=6438b279898eb358c7e00a6e072200d5" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>Natureé¦–æ¬¡æ­ç¤ºæŸ“è‰²è´¨è°ƒèŠ‚å› å­ï¼šSATB1è°ƒæ§Tç»†èƒï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—å¼€æ–°æŒ‚ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«ã€Tç»†èƒã€Bç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šåœ¨æ…¢æ€§ç—…æ¯’æ„ŸæŸ“å’Œç™Œç—‡ä¸­ï¼ŒCD8+ Tç»†èƒé•¿æœŸæš´éœ²äºæŠ—åŸåˆºæ¿€ä¸‹ä¼šé€æ¸åˆ†åŒ–ä¸ºè¡°ç«­Tç»†èƒï¼Œå…¶ç‰¹å¾æ˜¯åŠŸèƒ½å—æŸã€æŠ‘åˆ¶æ€§å—<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=1&amp;sn=5eb6a4142fdb2daa4594d018f4ca7f2a" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>å•èƒå¯å¡‘ | Nature | èµ·æºåŸºåº•ç»†èƒè§£æç™Œç—‡ä¸­ç¥ç»å†…åˆ†æ³Œ-ç°‡çŠ¶ç»†èƒè°±ç³»å¯å¡‘æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šBioJournal Link<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€Tç»†èƒã€ç¥ç»ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503137&amp;idx=1&amp;sn=c960e9fb56d2c0fd571831cd71be5b44" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=6&amp;sn=02d6d73bb12a3f637bee6f58d2c9d151" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>è·Ÿç€æ–‡çŒ®å­¦ä¹ VisiumHDå•ç»†èƒç©ºé—´è½¬å½•ç»„æ•°æ®å¤„ç†ï¼Œè¿™ä¸ªå¤§å®¶åšçš„ä¹Ÿè¶Šæ¥ä¹Ÿå¤šäº†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå¥½çš„ç©ºé—´ç»„å­¦ä»£ç å­¦ä¹ <br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495626&amp;idx=1&amp;sn=9a5f3884b0e1e8cea40d7336e507dc04" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>ã€Šè‡ªç„¶Â·å…ç–«å­¦ã€‹ï¼šåº·å¥ˆå°”å›¢é˜Ÿé¦–æ¬¡å‘ç°ï¼Œâ€œåˆ«åƒæˆ‘â€ä¿¡å·åˆ†å­CD47ï¼Œç«Ÿç„¶è¿˜èƒ½ä¿ƒè¿›Tç»†èƒè€—ç«­ï¼Œå‰Šå¼±æŠ—è‚¿ç˜¤å…ç–«ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€Tç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šä¸€æ¡è°ƒæ§Tç»†èƒè€—ç«­çš„æ–°é€šè·¯ç°èº«ï¼Œä¸ºæ”¹å–„å…ç–«æ²»ç–—æ•ˆæœæä¾›äº†æ–°çš„æ¢ç´¢æ–¹å‘ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503527&amp;idx=1&amp;sn=eaf3a923eb3e9dd36ebef58f18067652" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>Cancer Cell+1ï¼é™†å†›å†›åŒ»å¤§æ­ç¤ºèƒ¶è´¨ç˜¤çš„ç¥ç»å…ç–«é€ƒé€¸æ–°æœºåˆ¶ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä»Šæ—¥ç—…ç†<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€å…ç–«ã€ç¥ç»<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU1OTkyMTE4Mg==&amp;mid=2247488952&amp;idx=1&amp;sn=9e873f78c9df24641f9d2df54cff79aa" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>æ–‡çŒ®åˆ†äº«--ç©ºé—´å¤šç»„å­¦æŠ€æœ¯æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œç‰¹å¾ï¼šè‚¿ç˜¤å¾®ç¯å¢ƒä¸­ä¿ƒç‚æ€§è¶‹åŒ–å› å­æ´»æ€§çš„å…³é”®ä½œç”¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒç©ºé—´äº¤å“ä¹<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€è¶‹åŒ–å› å­ã€ç©ºé—´ç»„å­¦<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæ–‡çŒ®åˆ†äº«--ç©ºé—´å¤šç»„å­¦æŠ€æœ¯æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œç‰¹å¾ï¼šè‚¿ç˜¤å¾®ç¯å¢ƒä¸­ä¿ƒç‚æ€§è¶‹åŒ–å› å­æ´»æ€§çš„å…³é”®ä½œç”¨<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247499033&amp;idx=1&amp;sn=b96466d84df856b7b36d7592a72809d5" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 28 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (45æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE302715 ä¸€ç§è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨ T ç»†èƒå’Œ NK ç»†èƒçš„ååŒä½œç”¨è¿›è¡Œå¼ºæ•ˆç™Œç—‡å…ç–«æ²»ç–— [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)ã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michelle von Locquenghien ; Pascale Zwicky ; Ken Xie ; Diego Jaitin ; Fadi Sheban ; Florian Uhlitz ; Chamutal Gur ; Reut Sharet Eshed ; Eyal David ; Kfir Mazuz ; Jahan Adeeb Rahman ; Noam Solomon ; Roberto Avellino ; Assaf Weiner ; Ido AmitSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTumor-associated macrophages (TAMs) expressing the myeloid checkpoint TREM2 are key immunosuppressive cells in the tumor microenvironment (TME), driving tumor progression and contributing to poor prognosis in cancer patients. Due to their pivotal role, TAMs have emerged as a promising target for immunotherapies. However, current TAM-targeting monotherapies show only modest efficacy in clinical trials in solid tumors . Here, we have developed a new class of cancer immunotherapies: myeloid-targeted immunocytokines and NK-T cell enhancers (MiTEs). MiTEs are trans-acting immunocytokines with tumor-specific activation, allowing dual targeting of TAMs and lymphocytes by TREM2 antagonism and cytotoxic effector cell activation through IL-2. To avoid off-target toxicities, MiTEs contain an IL-2 masking moiety, which is cleaved by a TAM-specific protease. MiTEs demonstrate high efficacy in preclinical tumor models through extensive immune reprogramming spanning TAM, T and NK cell compartments. MiTEs show transformative potential for treating solid-cancers by inducing potent multi-arm anti-tumor immunity and minimizing toxicities.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302715" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE303870 ä¸€ç§é¶å‘è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçš„å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨Tç»†èƒå’ŒNKç»†èƒçš„ååŒä½œç”¨ï¼Œå®ç°å¼ºæ•ˆçš„ç™Œç—‡å…ç–«æ²»ç–—</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303870" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE303868 ä¸€ç§è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨ T ç»†èƒå’Œ NK ç»†èƒçš„ååŒä½œç”¨è¿›è¡Œå¼ºæ•ˆç™Œç—‡å…ç–«æ²»ç–— [CITE-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michelle von Locquenghien ; Pascale Zwicky ; Ken Xie ; Diego Jaitin ; Fadi Sheban ; Florian Uhlitz ; Chamutal Gur ; Reut Sharet Eshed ; Eyal David ; Kfir Mazuz ; Jahan Adeeb Rahman ; Noam Solomon ; Roberto Avellino ; Assaf Weiner ; Ido AmitSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensTumor-associated macrophages (TAMs) expressing the myeloid checkpoint TREM2 are key immunosuppressive cells in the tumor microenvironment (TME), driving tumor progression and contributing to poor prognosis in cancer patients. Due to their pivotal role, TAMs have emerged as a promising target for immunotherapies. However, current TAM-targeting monotherapies show limited efficacy, highlighting the need for strategies engaging multiple immune modalities. Here, we developed a new class of cancer immunotherapies: myeloid-targeted immunocytokines and NK-T cell enhancers (MiTEs). MiTEs are trans-acting immunocytokines with tumor-specific activation, allowing dual targeting of TAMs and lymphocytes by TREM2 antagonism and cytotoxic effector cell activation through IL-2. To avoid off-target toxicities, MiTEs contain an IL-2 masking moiety, which is cleaved by a TAM-specific protease. MiTEs demonstrate high efficacy in preclinical tumor models through extensive immune reprogramming spanning TAM, T and NK cell compartments. MiTEs show transformative potential for treating solid-cancers by inducing potent multi-arm anti-tumor immunity and minimizing toxicities.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303868" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE281973 è‚¿ç˜¤æµ¸æ¶¦æ€§ NK ç»†èƒ (tuNK) ä¸è„¾è„ NK ç»†èƒ (spNK) çš„åŠŸèƒ½å’Œè½¬å½•è°±æ¯”è¾ƒ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€NK cellã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yi Wang ; Li Tang ; Yugang GuoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNatural killer (NK) cells, a type of potent cytotoxic lymphocytes, are particularly promising for the treatment of cancers that lose or downregulate major histocompatibility complex class I (MHC-I) expression to evade T cell-mediated immunotherapy. However, the hostile and immune suppressive tumor microenvironment (TME) greatly hinders the function of tumor-infiltrating NK cells limiting the therapeutic efficacy against solid tumors. Here, we show that a fusion protein of interleukin-21 (IL-21âˆ’Fc), as a direct in vivo intervention, can safely and effectively reprogram NK cell metabolism and enhance their effector function in the TME. Our research demonstrates that combining IL-21âˆ’Fc with IL-15 superagonist (IL-15SA) or NK cell transfer leads to the eradication of MHC-I-deficient tumors and confers durable protection in syngeneic and xenograft tumor models. Mechanistically, we uncover that IL-21âˆ’Fc enhances NK cell effector function by upregulating glycolysis in a lactate dehydrogenase A (LDHA)-dependent manner. These findings not only underscore the considerable potential of IL-21âˆ’Fc as an in vivo therapeutic intervention to bolster NK cell-based immunotherapy, but also unveil an innovative strategy of metabolic reprogramming for NK cell rejuvenation within tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281973" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE254278 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäº¨å»·é¡¿ç—…ç¥ç»é€€è¡Œæ€§å˜ä¸­Tç»†èƒçš„ç‰©ç§ä¾èµ–æ€§å…ç–«æµ¸æ¶¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€single-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jiawei Li ; Yingqi Lin ; Sen YanSeries Type : Expression profiling by high throughput sequencingOrganism : Sus scrofaImmune infiltration of T cells in the brain has been observed in various pathological conditions, but whether this phenomenon occurs in Huntington disease (HD) remains unknown. To address this question, we conducted an investigation using HD knock-in pigs, which exhibit selective neurodegeneration similar to HD patients. Single-cell transcriptomes identified that glial cells are the most abundant cell type in the human and pig striatum, while neurons outnumber glial cells in the mouse striatum. HD knock-in pigs recapitulate the loss of specific types of striatal neurons (iSPN and dSPN) observed in HD patients, a phenomenon not observed in HD knock-in mice. The increased IFN-activated microglia subgroup in HD knock-in pigs was found to secrete CCL8 chemokines to recruit CD8+ T cells. These T cells release perforin and granzyme, leading to the degeneration of striatal neurons. Although HD-KI mouse striatum does not show elevated CCL8, administration of CCL8 resulted in an increase in CD8+ T cells and a reduction in neuronal cells. These findings suggest that species-dependent abundance of glial cells and the effects of mutant huntingtin on glial cells contribute to microglia-driven immune infiltration of CD8+ T cells, ultimately playing a critical role in the selective neurodegeneration in HD.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254278" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE248419 Zeb1-Cxcl1è½´é€šè¿‡è¯±å¯¼ä¹³è…ºç™Œä¸­M2å·¨å™¬ç»†èƒæåŒ–æ¥å‰Šå¼±æŠ—è‚¿ç˜¤å…ç–«ååº” II</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€macrophage<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusZeb1, a classic epithelial-mesenchymal transition (EMT) regulator, has recently been found to be involved in M2 macrophage polarization in the tumor immune microenvironment, thereby promoting tumor development. However, the underlying mechanism of Zeb1-induced M2 macrophage polarization remains largely unexplored. To identify the potential role of Zeb1 in remodeling the tumor immune microenvironment in breast cancer, we crossed the floxed Zeb1 allele homozygously into PyMT mice to generate PyMT;Zeb1cKO (MMTV-Cre; PyMT;Zeb1fl/fl) mice. We found that the recruitment of M2 macrophages was significantly reduced in tumors from PyMT;Zeb1cKO mice, along with weakening of the tumor suppressive effect. Mechanistically, Zeb1 plays a crucial role in transcriptionally promoting the expression of Cxcl1 in tumor cells and enhancing the secretion of Cxcl1 in serum. Eventually, Cxcl1 activated the JAK-Stat3 signature via Cxcr2 and then induced the M2 polarization of macrophages, which leads to T cell inactivation and impairs the antitumor immune response in breast cancer. Our results revealed the important role of Zeb1 in the remodeling of the breast cancer tumor microenvironment, suggesting a novel therapeutic intervention for the treatment of advanced cancers.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248419" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE248418 Zeb1-Cxcl1è½´é€šè¿‡è¯±å¯¼ä¹³è…ºç™Œä¸­M2å·¨å™¬ç»†èƒæåŒ–æ¥æŸå®³æŠ—è‚¿ç˜¤å…ç–«ååº” I</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€macrophage<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensZeb1, a classic epithelial-mesenchymal transition (EMT) regulator, has recently been found to be involved in M2 macrophage polarization in the tumor immune microenvironment, thereby promoting tumor development. However, the underlying mechanism of Zeb1-induced M2 macrophage polarization remains largely unexplored. To identify the potential role of Zeb1 in remodeling the tumor immune microenvironment in breast cancer, we crossed the floxed Zeb1 allele homozygously into PyMT mice to generate PyMT;Zeb1cKO (MMTV-Cre; PyMT;Zeb1fl/fl) mice. We found that the recruitment of M2 macrophages was significantly reduced in tumors from PyMT;Zeb1cKO mice, along with weakening of the tumor suppressive effect. Mechanistically, Zeb1 plays a crucial role in transcriptionally promoting the expression of Cxcl1 in tumor cells and enhancing the secretion of Cxcl1 in serum. Eventually, Cxcl1 activated the JAK-Stat3 signature via Cxcr2 and then induced the M2 polarization of macrophages, which leads to T cell inactivation and impairs the antitumor immune response in breast cancer. Our results revealed the important role of Zeb1 in the remodeling of the breast cancer tumor microenvironment, suggesting a novel therapeutic intervention for the treatment of advanced cancers.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248418" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE310106 DDX6 å‘ç”Ÿç›¸åˆ†ç¦»ä»¥è°ƒèŠ‚ AML ä¸­çš„ä»£è°¢å¯å¡‘æ€§å’Œè€è¯æ€§ [CRISPR ç­›é€‰]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Rui Su ; Chun-Wei (David) Chen ; Hongjie Bi ; Anthony ChanSeries Type : OtherOrganism : Homo sapiensChemoresistance in acute myeloid leukemia (AML) is a major cause of poor prognosis and frequent relapse among patients. Under stress conditions such as chemotherapy or radiotherapy, processing bodies (PBs) and stress granules (SGs) can sequester essential mRNAs and proteins to modulate leukemia cell survival. However, the precise role(s) of PBs and SGs in AML pathogenesis and chemotherapy response remains unclear. To systematically identify PB/SG-associated genes that are critical for AML survival, we selected 101 genes encoding RNA-binding proteins that are localized within PBs and SGs, and constructed a customized CRISPR library targeting these genes for both in vitro and in vivo CRISPR screening with AML cell line (Mono-Mac-6) and patient-derived xenograft (PDX) cells.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310106" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE304762 åˆ©ç”¨åŸºå› æ¡å½¢ç å’Œå•ç»†èƒè½¬å½•ç»„å­¦è§£æé£Ÿç®¡ç™Œå‰ç—…å˜ä¸­å‰ä½“ç»†èƒçš„åŠ¨æ€å˜åŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : OtherOrganism : Mus musculusEsophageal preneoplastic cells, despite appearing histologically normal, exhibit early genetic alterations and lineage plasticity, yet their origins and trajectories remain unclear. This study employs genetic barcoding combined with single-cell RNA sequencing to trace the lineage of esophageal preneoplastic cells and identify a distinct progenitor-like population with high plasticity. Through a newly developed scoring system, high-plasticity cells are mapped, revealing their contributions to proliferative and basal cell populations. The study identifies key molecular markers, including Nfib and Qk, that define these precursor cells. These findings provide critical insights into early tumorigenesis, highlighting the potential of precursor cells as biomarkers for early cancer detection and therapeutic targeting. By elucidating the cellular dynamics underlying esophageal cancer initiation, this research lays the foundation for strategies to prevent malignant progression, offering broader implications for improving cancer diagnostics and treatment approaches.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304762" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE291689 Pfkfb1 é€‰æ‹©æ€§åœ°è¯†åˆ«å«æœ‰èƒå†…ç”Ÿé•¿ç»†èŒçš„å·¨å™¬ç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šbacteriaã€regex:bacter(ia|ial|ium)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Li Fan ; Yang SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThrough releasing virulence molecules into host cells, intracellular bacteria interfere with host cellular functions and grow in the cells that engulf them. To ensure survival and virulence, these pathogens also manipulate host factors, but this process is not fully understood. In this study, we investigated the host molecular mechanisms required for intracellular bacterial growth in macrophages using Salmonella typhimurium (Salmonella) infection model and bacterial division reporter system. Upon Salmonella infection, Protein Phosphatase 6 (Pp6) was significantly reduced in macrophages containing growing bacteria. Conditional knockout of Pp6 increased host susceptibility to Salmonella-mediated killing, which was attributed to the poor resistance in Pp6-deficient macrophages. MicroRNA-31 (miR-31) was identified as a negative regulator of Pp6, and its conditional deletion promoted Salmonella clearance. Moreover, a yeast two-hybrid screening identified 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (Pfkfb1), a key metabolic regulator, as a substrate of Pp6. Pp6-deficient macrophages exhibited elevated Pfkfb1 expression. Furthermore, we found that macrophages containing growing Salmonella exclusively exhibited high Pfkfb1 expression. Pfkfb1 deletion reduced bacterial growth, likely due to increased NO levels, while also downregulating arginase-1 (Arg-1) expression and impairing arginine biosynthesis and metabolism in macrophages. Together, we investigated the role of Pp6-Pfkfb1 axis in orchestrating host metabolic adaptions and intracellular bacterial survival, which may provide therapeutic targets for infectious diseases against intracellular multidrug-resistant bacteria.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291689" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 35 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (8æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨8æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>Cergutuzumab Amunaleukin ä¸é˜¿æ›¿ä½åˆ©ç å•æŠ—è”åˆæ²»ç–—ç™Œèƒšé˜³æ€§æ™šæœŸ/è½¬ç§»æ€§å®ä½“è‚¿ç˜¤æ‚£è€…</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šCergutuzumab amunaleukinï¼ˆCAï¼‰æ˜¯ä¸€ç§å…ç–«ç»†èƒå› å­ï¼Œç”±ç™½ä»‹ç´ -2 å˜å¼‚å½¢å¼ç»„æˆï¼ˆè®¾è®¡ä¸ºé¿å… CD25 ç»“åˆå’Œ Treg åˆºæ¿€ï¼‰ï¼Œèåˆäºè‡´ç™ŒèƒšèƒæŠ—åŸï¼ˆCEAï¼‰é¶å‘æŠ—ä½“ã€‚è¯¥ Ib æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒå‰‚é‡é€’å¢ä¸æ‰©å±•ç ”ç©¶ï¼ˆNCT02350673ï¼‰è¯„ä¼°äº† CA åŠ é˜¿æ›¿å”‘ç å•æŠ—åœ¨æ™šæœŸ/è½¬ç§»æ€§ CEA é˜³æ€§å®ä½“è‚¿ç˜¤æ‚£è€…çš„å®‰å…¨æ€§ã€æ´»æ€§ã€è¯ä»£åŠ¨åŠ›å­¦å’Œè¯æ•ˆå­¦ã€‚æ‚£è€…ä¸æ–¹æ³•ï¼šæ‚£è€…æ¯ 2 å‘¨ï¼ˆæ¯ 2 å‘¨ï¼‰æ¥å— CA å‰‚é‡é€’å¢ï¼ˆ6â€“20/25 æ¯«å…‹ï¼‰ä¸å›ºå®šå‰‚é‡é˜¿æ›¿å”‘ç å•æŠ—ï¼ˆ840 æ¯«å…‹ï¼‰;æˆ–æ¯å‘¨é€’å¢å‰‚é‡ CAï¼ˆ10â€“15/20 æ¯«å…‹ï¼‰ä¸å›ºå®šå‰‚é‡é˜¿æ›¿å”‘ç å•æŠ—ï¼ˆ1200 æ¯«å…‹ï¼‰æ¯ 3 å‘¨ï¼ˆæ¯ 3 å‘¨ï¼‰é€’å¢å‰‚é‡ã€‚ä¸»è¦ç›®æ ‡ï¼šæœ€å¤§è€å—å‰‚é‡ï¼ˆMTDï¼‰;æ‰©å¼ æ¨èå‰‚é‡ï¼ˆRDEï¼‰;å®‰å…¨ã€‚ç»“æœï¼š24 åæ‚£è€…è¢«éšæœºåˆ†é…ä¸ºæ¯ 2 å‘¨æ¥å— CA åŠ é˜¿æ›¿å”‘ç å•æŠ—ï¼Œ45 åæ‚£è€…ä¸º CA QW åŠ é˜¿æ›¿å”‘ç å•æŠ—æ¯ 3 å‘¨<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991257205251354624/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>å¤å‘/éš¾æ²»æ€§å¤§ B ç»†èƒæ·‹å·´ç˜¤æ‚£è€… JULIET è¯•éªŒäº”å¹´åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´ã€Bç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991257298360709120/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ç›¸å…³èƒ†é“ç™Œçš„ä¸´åºŠåŸºå› ç»„å­¦ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šèƒ†é“ç™Œï¼ˆBTCï¼‰æ˜¯åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ï¼ˆPSCï¼‰æ‚£è€…çš„ä¸»è¦æ­»å› ã€‚ä¸ PSC ç›¸å…³çš„ BTC ç›®å‰å°šä¸å……åˆ†ï¼Œå¸¸è§„å’Œå…ç–«ç–—æ³•çš„é£é™©ä¸ç›Šå¤„å°šä¸æ˜ç¡®ã€‚æˆ‘ä»¬çš„ç›®æ ‡æ˜¯è¡¨å¾ PSC ç›¸å…³ BTCs çš„ä¸´åºŠç»“å±€å’ŒåŸºå› ç»„ã€‚å®éªŒè®¾è®¡ï¼šè¿™æ˜¯ä¸€é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œé’ˆå¯¹åœ¨ MD Anderson ç™Œç—‡ä¸­å¿ƒï¼ˆN=46ï¼‰å’Œç›æ ¼ä¸½ç‰¹å…¬ä¸»ç™Œç—‡ä¸­å¿ƒï¼ˆN=16ï¼‰æ¥å—æ²»ç–—çš„åŸºç¡€ PSC æ‚£è€…çš„ BTC æ‚£è€…ï¼Œä¸é PSC ç›¸å…³ BTC æ‚£è€…ï¼ˆN=146ï¼‰è¿›è¡Œäº†å¯¹æ¯”ã€‚æˆ‘ä»¬æ¯”è¾ƒäº† PSC ä¸é PSC çš„ç»“å±€ï¼Œä»¥åŠæœ‰æ— å…ç–«æ²»ç–—çš„ PSC æ²»ç–—ã€‚é¶å‘æµ‹åºï¼ˆN=139ï¼‰ã€å…¨åŸºå› ç»„æµ‹åºï¼ˆN=27ï¼‰åŠå…¨åŸºå› ç»„é…å¯¹ RNA æµ‹åºï¼ˆN=33ï¼‰çš„ç»„åˆï¼Œæç»˜äº† PSC ç›¸å…³ BTCs çš„åŸºå› ç»„å’Œè½¬å½•ç»„æ ¼å±€ã€‚ç»“æœï¼šåœ¨ PSC ç›¸å…³ BTC ä¸­ï¼Œå°†å…ç–«æ²»ç–—åŠ å…¥åŒ–ç–—ä¸æ”¹å–„ä¸€çº¿æ— è¿›å±•ç”Ÿå­˜æœŸç›¸å…³ï¼ˆN=22 å¯¹ 11ï¼Œä¸­ä½ PFS 12.2 å¯¹ 4.7 ä¸ªæœˆï¼‰ï¼Œ<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991257199857479680/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>éšç€åŒç‰¹å¼‚æ€§æŠ—ä½“ä¸Šå‡ï¼Œåˆ©å¦¥æ˜”å•æŠ—/å‰è¥¿ä»–æ»¨/å¥¥æ²™åˆ©é“‚çš„ä½¿ç”¨æ—¥è½ï¼šSUNMO è¯•éªŒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1990916707953258496/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>èƒ°è…ºç™Œä¸­çš„é›Œæ¿€ç´ ç”Ÿæˆå¡‘é€ äº†æŠ‘åˆ¶è‚¿ç˜¤çš„åŸºè´¨å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç”±äºç¼ºä¹æœ‰æ•ˆçš„æ²»ç–—å¹²é¢„ï¼Œèƒ°ç®¡è…ºç™Œï¼ˆPDACï¼‰æ˜¯å¯¼è‡´ç™Œç—‡ç›¸å…³æ­»äº¡çš„ä¸»è¦åŸå› ä¹‹ä¸€ã€‚PDAC è‚¿ç˜¤é«˜åº¦çº¤ç»´åŒ–ï¼Œé—´è´¨ä¸°åº¦è¢«å‡è®¾å¯¹æ‚£è€…ç»“å±€æœ‰å½±å“ã€‚ç„¶è€Œï¼ŒåŸºè´¨æˆçº¤ç»´ç»†èƒå¯èƒ½ä¿ƒè¿›è‚¿ç˜¤å¹¶æŠ‘åˆ¶è‚¿ç˜¤ï¼Œè¿™æˆ–è®¸èƒ½è§£é‡ŠåŸºè´¨é¶å‘æ²»ç–—ä»¤äººå¤±æœ›çš„ä¸´åºŠç»“æœã€‚æˆ‘ä»¬è§‚å¯Ÿåˆ°ï¼Œå¥³æ€§ PDAC æ‚£è€…çš„è¡€æ¸…é—´è´¨ç”Ÿç‰©æ ‡å¿—ç‰©æ°´å¹³æ˜¾è‘—é«˜äºç”·æ€§æ‚£è€…ã€‚è¿™ä¸€è§‚ç‚¹å¾—åˆ°äº†å¯¹å®ä½“ç™Œé—´è´¨ä¸°åº¦çš„è®¡ç®—æœºä¼°è®¡ï¼Œä»¥åŠç£å…±æŒ¯å¼¹æ€§æˆåƒå’Œç»„ç»‡æŸ“è‰²çš„æ”¯æŒï¼Œè¿™äº›æ–¹æ³•æ˜¾ç¤ºå¥³æ€§ PDAC æ‚£è€…çš„è‚¿ç˜¤ç»„ç»‡æ›´ä¸ºåšç¡¬ã€‚åŸºå› è¡¨è¾¾åˆ†ææ˜¾ç¤ºï¼Œé›Œæ¿€ç´ ä¿¡å·ä¼ å¯¼æŒ‡ç¤ºä¸€ä¸ªåŸºè´¨æˆçº¤ç»´æ¯ç»†èƒè¡¨å‹ï¼Œè¯¥è¡¨å‹ä¸ç›¸å¯¹æƒ°æ€§åˆ†å­äºšå‹ç›¸å…³ï¼Œä¸”é¢„åæ›´ä¸ºè‰¯å¥½ï¼Œè€Œè¯¥é¢„åç”± C å‹å‡é›†ç´  CLEC3B çš„åŸºè´¨è¡¨è¾¾ç»´æŒã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œé›Œæ¿€ç´ åœ¨è‚¿ç˜¤å†…è¢«æ£€æµ‹åˆ°ï¼Œèƒ°è…ºç™Œç»†èƒè¡¨è¾¾äº†ä¿ƒæˆé›Œæ¿€ç´ åˆæˆçš„å…³é”®é…¶ã€‚PDAC ä¸­çš„é›Œæ¿€ç´ äº§ç”Ÿç”±åŸºè´¨è¡ç”Ÿçš„åˆ†æ”¯é“¾æ°¨åŸºé…¸åˆ†è§£ä½œç”¨æ¨åŠ¨ï¼Œæœ€ç»ˆäº§ç”Ÿç±»å›ºé†‡æ¿€ç´ å‰ä½“ã€‚è¿™äº›æ•°æ®å…±åŒæ­ç¤ºäº†é‡è¦çš„æ¿€ç´ é©±åŠ¨å› ç´ ï¼Œé€šè¿‡é‡ç¼–ç¨‹è‚¿ç˜¤å¾®ç¯å¢ƒæ¥é™åˆ¶è‚¿ç˜¤è¿›å±•ï¼Œå¹¶ä¸º<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991264624819941376/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>åŠ æ‹¿å¤§é’å°‘å¹´å’Œé’å¹´ç™Œç—‡åè·¨æ€§åˆ«å’Œå¹´é¾„çš„æ”¶å…¥ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ é’å°‘å¹´å’Œå¹´è½»æˆäººï¼ˆAYAsï¼‰ç™Œç—‡åœ¨å…³é”®çš„è¿‡æ¸¡é˜¶æ®µå‡ºç°ï¼Œå¯¹è´¢åŠ¡å¥åº·äº§ç”ŸæŒä¹…å½±å“ã€‚ç›®å‰å°šä¸ç¡®å®š AYAs ä¸­çš„ç™Œç—‡æ˜¯å¦ä¼šå› æ€§åˆ«å’Œè¯Šæ–­å¹´é¾„éšæ—¶é—´åœ¨æ”¶å…¥ä¸Šè¡¨ç°å‡ºå·®å¼‚ã€‚æ–¹æ³• æˆ‘ä»¬å°†åŠ æ‹¿å¤§å›½å®¶ç™Œç—‡ç™»è®°å¤„ä¸ä¸ªäººç¨åŠ¡è®°å½•å…³è”ï¼Œä»¥è¯†åˆ« 1994 å¹´è‡³ 2013 å¹´é—´è¯Šæ–­çš„ AYAï¼ˆ15-39 å²ï¼‰ã€‚åœ¨ç¡®è¯Šå‰ä¸€å¹´ï¼Œå¹¸å­˜è€…åœ¨å¤šä¸ªç¤¾ä¼šäººå£å­¦ç‰¹å¾ä¸Šä¸ 10 åæ— ç™Œè€…è¿›è¡Œäº†å˜å¼‚æ¯”åŒ¹é…ã€‚å‚ä¸è€…çš„çºµå‘éšè®¿æ—¶é—´æœ€é•¿å¯è¿½æº¯è‡³è¯Šæ–­å 10 å¹´æˆ– 2015 å¹´ã€‚ä½¿ç”¨åŒç¨³å¥å·®åˆ†ä¼°ç®—ç›¸å¯¹å’Œç»å¯¹æ”¶å…¥å˜åŒ–ã€‚æˆ‘ä»¬å°†å¹´é¾„åˆ†ä¸ºä¸‰ç»„ï¼šé’å°‘å¹´ï¼ˆ15-17 å²ï¼‰ã€æ–°å…´é’å¹´ï¼ˆ18-29 å²ï¼‰å’Œé’å¹´æˆäººï¼ˆ30-39 å²ï¼‰ï¼Œåæ˜ äº†ä¸åŒçš„ AYA ç”Ÿå‘½é˜¶æ®µã€‚åˆ†ææŒ‰æ€§åˆ«å’Œè¯Šæ–­å¹´é¾„åˆ†å±‚ã€‚ç»“æœï¼šå¥³æ€§å¹¸å­˜è€… 60,240 äººï¼Œç”·æ€§å¹¸å­˜è€… 33,085 äººï¼Œåˆ†åˆ«åŒ¹é…åˆ°æ— ç™Œè€… 490,645 äººå’Œ 274,595 äººã€‚æ€»ä½“è€Œè¨€ï¼Œç”·æ€§å’Œå¥³æ€§æ”¶å…¥å‡å°‘ç‡åˆ†åˆ«ä¸º 6.9%ï¼ˆ95%ç½®ä¿¡åŒºé—´ï¼š5<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991265111577309184/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>FaceAge ä½œä¸ºå¤§å‹è‚¿ç˜¤å­¦é˜Ÿåˆ—é¢„åå’Œæ²»ç–—åˆ†å±‚çš„ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ï¼šäººç±»è¡°è€é€Ÿåº¦ä¸åŒï¼Œé¢éƒ¨ç‰¹å¾å¯èƒ½æ­ç¤ºç”Ÿç‰©å¹´é¾„å’Œç”Ÿç†å¥åº·çŠ¶å†µã€‚FaceAge æ˜¯ä¸€æ¬¾é€šè¿‡é¢éƒ¨ç…§ç‰‡ä¼°ç®—ç”Ÿç‰©å¹´é¾„çš„æ·±åº¦å­¦ä¹ ç³»ç»Ÿï¼Œå·²å±•ç°å‡ºä½œä¸ºç™Œç—‡é¢„åç”Ÿç‰©æ ‡å¿—ç‰©çš„æ½œåŠ›ã€‚æœ¬ç ”ç©¶æ¢è®¨äº†é¢éƒ¨å¹´é¾„ä¸å®é™…å¹´é¾„ï¼ˆFaceAge-Ageï¼‰ä¹‹é—´æç«¯ä¸ä¸€è‡´åœ¨é¢„æµ‹ç”Ÿå­˜ç‡å’Œæ—©æœŸæ­»äº¡ç‡ä¸­ï¼Œæ¶µç›– 28 ç§ç™Œç—‡ç±»å‹çš„å¤§å‹ä¸´åºŠæ•°æ®é›†ä¸­çš„é¢„åä»·å€¼ã€‚æ–¹æ³•ï¼šåˆ†æäº† 2008 å¹´è‡³ 2023 å¹´é—´æ¥å—æ”¾ç–—çš„ 24,556 åå¹´é¾„â‰¥60 å²çš„ç™Œç—‡æ‚£è€…çš„æ•°æ®ã€‚åœ¨ä¸åŒè¯Šæ–­/ä¸´åºŠèƒŒæ™¯ä¸‹ï¼Œæ¯”è¾ƒäº† FaceAge ä¼°è®¡å€¼ä¸æ—¶é—´å¹´é¾„ï¼Œå¹¶è¿›è¡Œäº†ç”Ÿå­˜åˆ†æã€‚æ‰€æœ‰æµ‹è¯•å‡ä¸ºåŒé¢æµ‹è¯•ã€‚ç»“æœ FaceAge åœ¨ 65%çš„å¹´é¾„ä¸­æ¯”å®é™…å¹´é¾„æ›´è€ï¼ˆä¸­ä½æ•°ä¸º 74 å²å¯¹ 70 å²ï¼‰ã€‚å¹´è½»æ‚£è€…ã€å¥³æ€§ã€é¢„åè¾ƒå·®ä¸”æ¥å—ç¼“å’Œæ„å›¾æ²»ç–—çš„æ‚£è€…ï¼Œè„¸é¾„-å¹´é¾„â‰¥10 å²çš„å¯èƒ½æ€§æ›´é«˜ã€‚é¢å¹´é¾„å¹´é¾„â‰¥10 å²æ‚£è€…å­˜æ´»ç‡æ˜¾è‘—è¾ƒä½ï¼Œè€Œé¢å¹´é¾„å¹´é¾„â‰¤-5 å²æ‚£è€…å­˜æ´»ç‡è¾ƒä½³ã€‚åœ¨å¤šå˜é‡åˆ†æä¸­ï¼ŒFaceAge-Ageâ‰¥10<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991265117394808832/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨ï¼šå…¨çƒä½¿ç”¨æ•°æ®åˆ†æã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ç”Ÿç‰©åˆ¶å‰‚æå¤§åœ°æ”¹å–„äº†ç™Œç—‡ç®¡ç†ï¼Œä½†æˆæœ¬è¾ƒé«˜ã€‚ç”Ÿç‰©ç±»ä¼¼è¯æˆæœ¬è¾ƒä½ï¼Œä¸”ä¸å‚è€ƒäº§å“ç›¸æ¯”æ²¡æœ‰ä¸´åºŠæ„ä¹‰ä¸Šçš„å·®å¼‚ã€‚ç„¶è€Œï¼Œå®ƒä»¬å¹¶ä¸å®Œå…¨ç›¸åŒï¼Œå¯¼è‡´ä¸´åºŠåŒ»ç”Ÿå’Œæ‚£è€…å¯¹ä½¿ç”¨å®ƒä»¬æŒçŠ¹è±«æ€åº¦ã€‚ç›®çš„ æµ‹é‡ç¾å›½åŠç±»ä¼¼ç›‘ç®¡æ¡†æ¶å›½å®¶ä¸­è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯ç›¸è¾ƒäºå‚è€ƒäº§å“çš„é‡‡ç”¨æƒ…å†µã€‚æ–¹æ³• æˆ‘ä»¬äº 2022 å¹´ 10 æœˆè‡³ 2023 å¹´ 9 æœˆæœŸé—´ï¼Œåœ¨ 13 ä¸ªå›½å®¶å¯¹äº”ç§å«ç”Ÿç‰©ç±»ä¼¼è¯çš„è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©åˆ¶å‰‚è¿›è¡Œäº†æ¨ªæ–­é¢é”€å”®åˆ†æï¼šè´ä¼ç å•æŠ—ã€è²æ ¼æ‹‰æ–¯æ±€ã€å‘éæ ¼æ‹‰æ–¯æ±€ã€åˆ©å¦¥æ˜”å•æŠ—å’Œæ›²å¦¥ç å•æŠ—ã€‚æˆ‘ä»¬ä½¿ç”¨äº† IQVIA MIDASÂ®å…³äºå›½å®¶å±‚é¢å­£åº¦é”€å”®é‡å’Œä»·å€¼çš„æ•°æ®ã€‚ç»“æœ åœ¨ 13 ä¸ªå›½å®¶ä¸­ï¼Œç¾å›½åœ¨è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨æ¯”ä¾‹ï¼ˆæŒ‰é”€å”®å•ä½è®¡ 75%å¯¹ä¸­ä½æ•° 86%ï¼‰å’Œæ”¯å‡ºæ¯”ä¾‹ï¼ˆ58%å¯¹ 76%ï¼‰æ–¹é¢æ’åç¬¬åã€‚ç¾å›½ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨ç‡ä¸ºï¼šéæ ¼ç‘å¸æ±€ 84%ï¼ˆå¯¹æ¯” 95%ï¼‰ï¼Œè´ä¼å•æŠ— 83%ï¼ˆå¯¹æ¯” 86%ï¼‰ï¼Œåˆ©å¦¥æ˜”å•æŠ— 75%ï¼ˆå¯¹æ¯” 93%ï¼‰ï¼Œæ›²å¦¥ç å•æŠ—<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1991265127071068160/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (7æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨7æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ç§‘å­¦å®¶é‡æ–°æ¿€æ´»ç–²æƒ«çš„Tç»†èƒï¼Œä»¥å¢å¼ºç™Œç—‡å…ç–«åŠ›ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immunity<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a particular molecular signal to weaken T cells, and that interrupting this signal helps the cells stay active.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251120002828.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>RNAæµ‹åºæ­ç¤ºäº†è‚Œè‚‰å¹²ç»†èƒå¦‚ä½•å¼•å¯¼å·¨å™¬ç»†èƒä¿ƒè¿›èŒèšªå°¾éƒ¨å†ç”Ÿã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing reveals how muscle stem cells use c1qtnf3 to shift macrophages toward regeneration, enabling African clawed frog tadpoles to regrow functional tails...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/rna-sequencing-reveals-how-muscle-stem-cells-guide-macrophages-to-drive-tadpole-tail-regeneration/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>RNAæµ‹åºä¸ºä»¥å¾€æ— æ³•ç¡®è¯Šçš„ç½•è§ç—…ç—…ä¾‹æä¾›äº†åŠŸèƒ½æ€§è§è§£å’Œè¯Šæ–­ä¾æ®ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing uncovers hidden splicing and regulatory defects, improving diagnostic clarity for rare disease cases when DNA tests fall short.<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/rna-sequencing-provides-functional-insights-and-diagnostic-resolution-in-previously-unsolved-rare-disease-cases/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>Parse Bioscienceså…¬å¸å®£å¸ƒæ¨å‡ºä¸FFPEå…¼å®¹çš„æ¡å½¢ç æŠ€æœ¯ï¼Œç”¨äºå…¨è½¬å½•ç»„å•ç»†èƒåˆ†æã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štranscriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing of FFPE tissues gains whole transcriptome, single cell resolution through...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/parse-biosciences-announces-ffpe-compatible-barcoding-technology-for-whole-transcriptome-single-cell-analysis/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ä¸€ç§ç®€å•çš„åˆ†å­åœ¨è€é¼ èº«ä¸Šå±•ç°å‡ºæ˜¾è‘—çš„é˜¿å°”èŒ¨æµ·é»˜ç—…é€†è½¬ä½œç”¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have developed a new molecule that breaks down beta-amyloid plaques by binding to excess copper in the brain. The treatment restored memory and reduced inflammation in rats, while also proving non-toxic and able to cross the bloodâ€“brain barrier. Because itâ€™s far simpler and potentially cheaper than existing drugs, researchers are now pursuing partnerships to begin human trials.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251118220052.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>ç‚ç—‡ä½¿éª¨é«“æˆä¸ºç–¾ç—…æ»‹ç”Ÿçš„æ¸©åºŠã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to quietly gain dominance with age. Reprogrammed stromal cells and interferon-responsive T cells create a self-sustaining inflammatory loop that weakens blood production. Surprisingly, the mutant cells themselves may not be the main instigators.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251118220049.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>æŠ—ä½“æ–°çªç ´æˆ–å°†æœ€ç»ˆå‡ç¼“å¤šå›Šè‚¾ç—…çš„å‘å±•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šantibody<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving polycystic kidney disease. Early mouse studies suggest it may halt or even reverse cyst expansion without harming healthy tissue.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251118220046.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ç”Ÿä¿¡</td>
<td>11</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>11</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>8</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>8</td>
</tr>
<tr>
<td>cancer</td>
<td>8</td>
</tr>
<tr>
<td>epigenome</td>
<td>8</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>7</td>
</tr>
<tr>
<td>tumor</td>
<td>5</td>
</tr>
<tr>
<td>macrophage</td>
<td>5</td>
</tr>
<tr>
<td>ç¥ç»</td>
<td>5</td>
</tr>
<tr>
<td>sequencing</td>
<td>4</td>
</tr>
<tr>
<td>NK cell</td>
<td>4</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>4</td>
</tr>
<tr>
<td>immune</td>
<td>4</td>
</tr>
<tr>
<td>é€šè·¯</td>
<td>3</td>
</tr>
<tr>
<td>inflammation</td>
<td>3</td>
</tr>
<tr>
<td>regex:immuno(logy</td>
<td>therapy</td>
</tr>
<tr>
<td>æŠ—ä½“</td>
<td>3</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (28æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493027&amp;idx=1&amp;sn=fe2aa45924eb23bcf06e5034464f968e" target="_blank" rel="noopener noreferrer">æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=4&amp;sn=3212c3dc84df1bdff5591f883548d08d" target="_blank" rel="noopener noreferrer">åˆšåˆšå‘è¡¨çš„8.9åˆ†ç”Ÿä¿¡ï¼Œé™¤äº†è¯†åˆ«æŸåŸºå› é˜³æ€§ç»†èƒï¼Œè¯†åˆ«æŸé€šè·¯/è¡¨å‹é˜³æ€§ç»†èƒä¹Ÿæ˜¯å‘æ–‡çš„å¥½æ€è·¯ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=3&amp;sn=8851b792a937b9cf3935b78a328b47fc" target="_blank" rel="noopener noreferrer">33+ç”Ÿä¿¡ï¼Œ è¯†åˆ«ä»ç™Œå‰ç—…å˜åˆ°è‚¿ç˜¤ä¸åŒæ¶æ€§ç¨‹åº¦ç›¸å…³çš„ç»†èƒäºšå‹ï¼Œé’ˆå¯¹IL-33+å†…çš®ç»†èƒä¿ƒè¿›ç–¾ç—…è¿›å±•è¿›è¡Œå®éªŒéªŒè¯ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490875&amp;idx=1&amp;sn=f8d0ae48f05b2a069eb2421d47431995" target="_blank" rel="noopener noreferrer">ç©ºé—´è½¬å½•ç»„å¹³å°æ€ä¹ˆé€‰ï¼ŸåŒ—å¤§å›¢é˜Ÿ5å¤§å¹³å°ç³»ç»Ÿæ€§æµ‹è¯„Visium HDã€Stereo-seq ã€CosMx 6Kã€Xenium 5K</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547083&amp;idx=1&amp;sn=4c15c623ab9c3ae5e59dc34b5f7068e4" target="_blank" rel="noopener noreferrer">ä½¿ç”¨pythonè¯»å–ç–‘éš¾æ‚ç—‡çš„å•ç»†èƒæ•°æ®ï¼ˆGSM7870858ï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555117&amp;idx=1&amp;sn=236d239fabd95df1c48953be166e40f2" target="_blank" rel="noopener noreferrer">Cell ï½œ åå¤§åŸºå› ï¼šStereo-seq V2ä»¥å•ç»†èƒç²¾åº¦é‡å¡‘FFPEç©ºé—´å…¨è½¬å½•å®‡å®™</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=4&amp;sn=6f4cb14277329070821137d0cd9fb90f" target="_blank" rel="noopener noreferrer">CellæŠ€æœ¯çªç ´ï¼ŒSTAMPè®©ç™¾ä¸‡å•ç»†èƒåˆ†æä¸æ˜¯é—®é¢˜!</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490954&amp;idx=1&amp;sn=118acfee15aedb9c440d4064d629b94b" target="_blank" rel="noopener noreferrer">Natureæœ€æ–°ï¼å¯’é—¨å¥³åšå£«è§£å†³å›½å®¶ç”Ÿç‰©ä¿¡æ¯å­¦é¢†åŸŸ50å¹´â€œå¡è„–å­â€æŠ€æœ¯ï¼å‰é€”æ— é‡ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510323&amp;idx=3&amp;sn=a2b9fb0e12b4953421db47693b4c99c1" target="_blank" rel="noopener noreferrer">å¤§è§„æ¨¡è¡€æµ†è›‹ç™½è´¨ç»„å­¦åˆ†æï¼éƒé‡‘æ³°&amp;è°­å…°å›¢é˜Ÿé¦–æ¬¡ç³»ç»Ÿæ€§æ­ç¤ºç™«ç—«å‘ç—…å‰è¡€æµ†è›‹ç™½è´¨çš„å˜åŒ–è§„å¾‹ï¼Œå‘ç°103ç§ä¸ç™«ç—«å‘ç—…é£é™©æ˜¾ç€ç›¸å…³</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533766&amp;idx=1&amp;sn=35f3d90d69dfa8c0a817ac5ded716020" target="_blank" rel="noopener noreferrer">HIVæ„ŸæŸ“å…ç–«å­¦æ— ååº”è€…çš„å…ç–«å¼‚è´¨æ€§åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498508&amp;idx=1&amp;sn=d98e432681dfea826b2b4ec962c89c87" target="_blank" rel="noopener noreferrer">GEOæ•°æ®ä¸ä¼šå¤„ç†ï¼Ÿä¸€ä¸ªRåŒ…å¸®ä½ æå®šå®ƒ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyMTI1MTYxNA==&amp;mid=2247519906&amp;idx=1&amp;sn=8dc18472efc6d9718026bb21a6bfc77a" target="_blank" rel="noopener noreferrer">Molecular Cellï¼šç›‘æµ‹çº¿ç²’ä½“ç¿»è¯‘çš„å¤æ‚æ€§ä¸åŠ¨æ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=8&amp;sn=1c36463066c10c11f726d627dafaf192" target="_blank" rel="noopener noreferrer">åˆšåˆšå‘è¡¨çš„14+ç”Ÿä¿¡åˆ†æï¼Œè¯†åˆ«MMP11+æˆçº¤ç»´ç»†èƒè¿›è¡Œåˆ†æå’ŒéªŒè¯ï¼Œæœ¬æ–‡æ€è·¯æ–°é¢–ï¼Œå€¼å¾—è®¤çœŸå­¦ä¹ æ¨¡ä»¿ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=2&amp;sn=9e5021568a2dd7bd92a02068678b49d0" target="_blank" rel="noopener noreferrer">ä»‹ç»ä¸¤ä¸ªç”Ÿä¿¡çƒ­ç‚¹å‘æ–‡æ€è·¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568990&amp;idx=1&amp;sn=242deb67a33191560e9039084fa1bfbb" target="_blank" rel="noopener noreferrer">ä»åªèƒ½æ´»6ä¸ªæœˆï¼Œåˆ°ç”Ÿå­˜æœŸå»¶é•¿åä½™å€ï¼è¿™ç±»è‚¿ç˜¤æ­£è¿æ¥æ²»ç–—æ›™å…‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507420&amp;idx=2&amp;sn=5965a20049a60eb207352e6f9d8b0286" target="_blank" rel="noopener noreferrer">Cellï¼šå¤šç»„ç»‡å™¨å®˜å…ç–«ç»†èƒå›¾è°±æ­ç¤ºç³»ç»Ÿå…ç–«å»ºç«‹ä¸è€å—æ–°æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523446&amp;idx=1&amp;sn=e26702510c751167b49786d692f31679" target="_blank" rel="noopener noreferrer">åŸºäºRè¯­è¨€çš„å¾®ç”Ÿç‰©ç»„æ•°æ®æŒ–æ˜çš„æœ€ä½³æµç¨‹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU3OTYwNjk1NA==&amp;mid=2247523431&amp;idx=2&amp;sn=1d72492971e1d7ea67e496bb433b123f" target="_blank" rel="noopener noreferrer">æ–°åˆ†å­æŠ—ä½“æ–°çºªå…ƒï½œBPI 2026æˆéƒ½ç«™é¦–æ‰¹30+é¢†è¢–å°±ä½ï¼å…±ç­‘æŠ—ä½“è¯ç‰©â€œç¬¬å››æâ€å¼ºåŠ¿å´›èµ·ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=7&amp;sn=88fbc3c74e35ceb19aef9c32edba0639" target="_blank" rel="noopener noreferrer">67åˆ†å·¨ä½œï¼Œå¸¦ä½ ç”¨çˆ†ç«çš„ä»£è°¢é‡ç¼–ç¨‹å®ç°å¼¯é“è¶…è½¦</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=6&amp;sn=70c5687af0bc8c1bc2fe1e6f820f3e54" target="_blank" rel="noopener noreferrer">Nature Medicineï¼šå¾å…µæ²³é™¢å£«/é©¬é£æ•™æˆä¹³è…ºç™Œå¤§ä½œâ€”â€”å…ç–«è”åˆèŠ‚æ‹åŒ–ç–—</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=5&amp;sn=c8baeae3a009b2c14f6cf02069641ccd" target="_blank" rel="noopener noreferrer">ç¥ç»é€€è¡Œæ€§ç–¾ç—…æ–°çº¿ç´¢ï¼šè„‘è¡€ç®¡å†…çš®TDP-43ï¼Œè¡€è„‘å±éšœçš„â€œéšå½¢æ€æ‰‹â€ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650362&amp;idx=1&amp;sn=45171e822dff9361abcccee992de67a2" target="_blank" rel="noopener noreferrer">Nature èƒŒé èƒŒï¼šéª†åˆ©ç¾¤é™¢å£«å›¢é˜Ÿå®ç°ç¥ç»ç¯è·¯é‡ç¼–ç¨‹ | ä¸€ä½œä¹‹ä¸€å·²å›å›½åŠ å…¥è¥¿æ¹–å¤§å­¦</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503137&amp;idx=2&amp;sn=a71b68980ff704b100b13c1dd83b4532" target="_blank" rel="noopener noreferrer">è½¬å½•å› å­ | Nat.Genet. | åˆ©ç”¨scTF-seqè§£æè½¬å½•å› å­å‰‚é‡å¯¹ç»†èƒé‡ç¼–ç¨‹å¼‚è´¨æ€§çš„å½±å“</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790173&amp;idx=4&amp;sn=5e1e337ff563e13bd8598d4f2fb33029" target="_blank" rel="noopener noreferrer">é’å²›å¤§å­¦Ã—å¤æ—¦å¤§å­¦åˆä½œCellå­åˆŠï¼šæ­ç¤ºç™«ç—«å‘ä½œç›¸å…³çš„è¡€æµ†è›‹ç™½è´¨ç»„</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790173&amp;idx=3&amp;sn=df3241e5adbe5a2e5f949f5cd23bf2b6" target="_blank" rel="noopener noreferrer">è¥¿æ¹–å¤§å­¦Ã—åŒ—äº¬å¤§å­¦åˆä½œNatureå­åˆŠï¼šAIä»å¤´è®¾è®¡è›‹ç™½ï¼Œå®ç°çº¿ç²’ä½“åŸºå› ç²¾å‡†ç¼–è¾‘</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821407&amp;idx=2&amp;sn=f82e06fe827063dcec1c77ecb91dd50a" target="_blank" rel="noopener noreferrer">ç”Ÿä¿¡æ•°æ®å¦‚ä½•æ”¯æ’‘å›½è‡ªç„¶åŸºç¡€ç ”ç©¶ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821407&amp;idx=1&amp;sn=e665d0faabe7d3376829edb50116da9d" target="_blank" rel="noopener noreferrer">å¦‚ä½•é€šè¿‡ç»„å­¦æ•°æ®åˆ†æï¼ŒæŒ–æ˜å›½è‡ªç„¶æ€è·¯ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490052&amp;idx=1&amp;sn=b7d0dee35ee7a128453af36e762d5bb2" target="_blank" rel="noopener noreferrer">èŒç¾¤ç§»æ¤åœ¨ç¥ç»ç³»ç»Ÿç–¾ç—…æ²»ç–—å’Œé¢„é˜²ä¸­çš„ä½œç”¨æœºç†</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (35æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289049" target="_blank" rel="noopener noreferrer">GSE289049 åˆ©ç”¨åŸºå› æ¡å½¢ç å’Œå•ç»†èƒè½¬å½•ç»„å­¦è§£æé£Ÿç®¡ç™Œå‰ç—…å˜ä¸­å‰ä½“ç»†èƒçš„åŠ¨æ€å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288193" target="_blank" rel="noopener noreferrer">GSE288193 ç¥ç»å…ƒ GDF-15 é€’é€æ”¹å˜å¤–å‘¨ CD4+ T ç»†èƒè¡¨å‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282621" target="_blank" rel="noopener noreferrer">GSE282621 5-HT å†æ‘„å–é˜»æ–­ç ´ååŸºäºåŸºå› ç»„ç¨³å®šæ€§çš„è›‹ç™½è´¨ç¨³æ€ï¼Œé€šè¿‡é‡å¡‘ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–è¯±å¯¼ç»†èƒç„¦äº¡ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282619" target="_blank" rel="noopener noreferrer">GSE282619 5-HT å†æ‘„å–é˜»æ–­ç ´ååŸºäºåŸºå› ç»„ç¨³å®šæ€§çš„è›‹ç™½è´¨ç¨³æ€ï¼Œé€šè¿‡é‡å¡‘ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–è¯±å¯¼ç»†èƒç„¦äº¡ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282082" target="_blank" rel="noopener noreferrer">GSE282082 ç¯çŠ¶RNA circTNK2 ä¿ƒè¿›å…ç–«é€ƒé€¸ï¼Œå¹¶å¯ä½œä¸ºä»–è«æ˜”èŠ¬è€è¯ERé˜³æ€§ä¹³è…ºç™Œçš„çº³ç±³æ²»ç–—é¶ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141341" target="_blank" rel="noopener noreferrer">GSE141341 ä½å‰‚ã€æ€§åˆ«å’Œå¾®ç”Ÿç‰©ç»„å¯¹æ’æ²³çŒ´SIVç–«è‹—è¯±å¯¼å…ç–«å’Œä¿æŠ¤æ•ˆåŠ›çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310442" target="_blank" rel="noopener noreferrer">GSE310442 SARS-CoV-2 ç–«è‹—æ¥ç§åæŠ—åŸååº”æ€§ CD4 T ç»†èƒåœ¨æœ‰æˆ–æ— å†æ¬¡åˆºæ¿€çš„æƒ…å†µä¸‹è¡¨ç°å‡ºä¸åŒçš„è¡¨å‹çŠ¶æ€ [æ··åˆæ ·æœ¬]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310441" target="_blank" rel="noopener noreferrer">GSE310441 SARS-CoV-2 ç–«è‹—æ¥ç§åæŠ—åŸååº”æ€§ CD4 T ç»†èƒåœ¨æœ‰æˆ–æ— å†æ¬¡åˆºæ¿€çš„æƒ…å†µä¸‹è¡¨ç°å‡ºä¸åŒçš„è¡¨å‹çŠ¶æ€ [ä¸åŒæ ·æœ¬]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310364" target="_blank" rel="noopener noreferrer">GSE310364 IL-15 ä¸­å’Œä½œç”¨å¯å‡è½»è„‘å†…æ€¥æ€§æ…¢ç—…æ¯’ç‚ç—‡å’Œä¿¡å·ä¼ å¯¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270194" target="_blank" rel="noopener noreferrer">GSE270194 è¡€å°æ¿å¯Œé›†è¡€æµ†å’Œè¡€å°æ¿è´«ä¹è¡€æµ†ä¸­çš„å°ç»†èƒå¤–å›Šæ³¡ä¸»è¦æ¥æºäºè¡€å°æ¿ï¼Œå¹¶èƒ½ä¿æŠ¤æ»‘è†œç»†èƒå…å—IL-1Î²è¯±å¯¼çš„ç‚ç—‡æŸä¼¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310491" target="_blank" rel="noopener noreferrer">GSE310491 å—ä½“æ¿€é…¶å¤åˆç‰©è°ƒæ§æ‹Ÿå—èŠ¥å½¢æˆå±‚æ´»æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307000" target="_blank" rel="noopener noreferrer">GSE307000 è‚ é“å·¨å™¬ç»†èƒè°ƒèŠ‚å¸•é‡‘æ£®ç—…ä¸­çš„è„‘çªè§¦æ ¸è›‹ç™½ç—…å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302403" target="_blank" rel="noopener noreferrer">GSE302403 æ·¡æ°´æµ·ç»µ Ephydatia muelleri åœ¨å…‰ç…§å’Œé»‘æš—æ¡ä»¶ä¸‹å‘è‚²è¿‡ç¨‹ä¸­è—»ç±»å†…å…±ç”Ÿä½“çš„åˆ†å­å’Œç©ºé—´æ•´åˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284163" target="_blank" rel="noopener noreferrer">GSE284163 è‡ªèº«å…ç–«æ€§è‚ç‚å°é¼ è‚è„è°ƒèŠ‚æ€§Tç»†èƒçš„æ™ºèƒ½RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282741" target="_blank" rel="noopener noreferrer">GSE282741 MeninæŠ‘åˆ¶å‰‚DS-1594bä¸Venetoclaxè”åˆä½¿ç”¨å¯ä¿ƒè¿›åˆ†åŒ–ï¼Œå¹¶åœ¨å…·æœ‰MLL1å’ŒNPM1é‡æ’çªå˜çš„æ€¥æ€§é«“ç³»ç™½è¡€ç—…ç»†èƒä¸­è¯±å¯¼ååŒè‡´æ­»ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272082" target="_blank" rel="noopener noreferrer">GSE272082 å•æ ¸å¤šç»„å­¦æ­ç¤ºæ•£å‘æ€§æ—©å‘æ€§é˜¿å°”èŒ¨æµ·é»˜ç—…ä¸‰ä¸ªè„‘åŒºçš„è°ƒæ§ç¨‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285557" target="_blank" rel="noopener noreferrer">GSE285557 æ–°ä¸€ä»£æµ‹åºæŠ€æœ¯ä¿ƒè¿›äº†å¯¹é»‘æš—æˆ–è“å…‰å¤„ç†ä¸‹ B73 å’Œ Zmcryq çªå˜ä½“è½¬å½•ç»„çš„å®šé‡åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310051" target="_blank" rel="noopener noreferrer">GSE310051 é«˜æ¸—åº”æ¿€è¯±å¯¼ 3D æŸ“è‰²è´¨ç›¸äº’ä½œç”¨çš„å¤§è§„æ¨¡é‡ç»„ [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310049" target="_blank" rel="noopener noreferrer">GSE310049 é«˜æ¸—åº”æ¿€è¯±å¯¼ 3D æŸ“è‰²è´¨ç›¸äº’ä½œç”¨çš„å¤§è§„æ¨¡é‡ç»„ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309786" target="_blank" rel="noopener noreferrer">GSE309786 PNPLA3-I148M åŸºå› å˜å¼‚é‡å¡‘è„‚è´¨ä»£è°¢ï¼Œé©±åŠ¨äººç±»è‚ç»†èƒç¨‹åºæ€§ç»†èƒæ­»äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309785" target="_blank" rel="noopener noreferrer">GSE309785 Tatè¡¨è¾¾å¯¹å®¿ä¸»è½¬å½•ç»„å›¾è°±çš„å½±å“ï¼Œä»¥åŠç»†èƒåœ¨æ½œä¼æœŸå„é˜¶æ®µçš„è½¬å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305126" target="_blank" rel="noopener noreferrer">GSE305126 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_RNA_seq_G609G_LA_EXP2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304993" target="_blank" rel="noopener noreferrer">GSE304993 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_RNA_seq_G609G_LA_EXP1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304972" target="_blank" rel="noopener noreferrer">GSE304972 å±‚ç²˜è›‹ç™½ A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_H3K9ac_ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289309" target="_blank" rel="noopener noreferrer">GSE289309 RNA-seq åˆ†æå°é¼ è‚ºå†…çš®ç»†èƒï¼Œä»¥ç ”ç©¶ ENG ä¾èµ–æ€§å’Œ ENG éä¾èµ–æ€§ BMP9 è¯±å¯¼é¶åŸºå› ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287935" target="_blank" rel="noopener noreferrer">GSE287935 CTCF è€¦åˆé•¿ç¨‹ç¯æŒ¤å‡ºå’Œæ‰©æ•£æ¥ä»‹å¯¼å¤šæ ·åŒ–çš„ Igk åº“ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282121" target="_blank" rel="noopener noreferrer">GSE282121 CT26_b2m-/- è‚¿ç˜¤æµ¸æ¶¦ NK (tuNK) çš„å•ç»†èƒæ°´å¹³åŸºå› è¡¨è¾¾è°±ï¼Œæ¥å— IL-21 æ²»ç–—æˆ– IL-21 å’Œ IL-15 è”åˆæ²»ç–—ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281737" target="_blank" rel="noopener noreferrer">GSE281737 ç‹¬ç‰¹çš„DNAç”²åŸºåŒ–ç‰¹å¾å¯èƒ½æ— æ³•ç‰¹å¼‚æ€§åœ°è¡¨å¾ä¸åŒé—ä¼ å˜å¼‚ä¸­çš„BLBS</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278999" target="_blank" rel="noopener noreferrer">GSE278999 å±‚ç²˜è›‹ç™½ A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_ChIP_seq_H3K9ac_H3K27ac_LA]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278998" target="_blank" rel="noopener noreferrer">GSE278998 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_ChIP_seq_H3K9me3_LA]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249274" target="_blank" rel="noopener noreferrer">GSE249274 å°¼éæ—é€šè¿‡è°ƒèŠ‚å¤šç§ä¿¡å·é€šè·¯æ”¹å–„é«˜è¡€å‹å¼•èµ·çš„å¿ƒè„é‡å¡‘â€”â€”å¿ƒè„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248534" target="_blank" rel="noopener noreferrer">GSE248534 å±‚ç²˜è›‹ç™½A/Cè°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248533" target="_blank" rel="noopener noreferrer">GSE248533 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [04scRNA_seq_D10]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248530" target="_blank" rel="noopener noreferrer">GSE248530 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [bulkPolyA_RNA_seq_LA_ES]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248421" target="_blank" rel="noopener noreferrer">GSE248421 USP51-GRP78è½´é€šè¿‡è°ƒèŠ‚ABCB1çš„æ´»æ€§ä¿ƒè¿›ä¸‰é˜´æ€§ä¹³è…ºç™Œç»†èƒå¯¹é˜¿éœ‰ç´ çš„è€è¯æ€§ã€‚</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-20 21:33</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>